Previous Close | 237.10 |
Open | 238.50 |
Bid | 236.00 x 0 |
Ask | 236.10 x 0 |
Day's Range | 236.00 - 238.80 |
52 Week Range | 212.90 - 293.55 |
Volume | |
Avg. Volume | 1,498,885 |
Market Cap | 190.39B |
Beta (5Y Monthly) | 0.16 |
PE Ratio (TTM) | 16.48 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 9.60 (4.05%) |
Ex-Dividend Date | Mar 14, 2024 |
1y Target Est | N/A |
Novo Nordisk, Eli Lilly's, Viking, Altimmune, Roche and Amgen are included in this Analyst Blog.
Though obesity drugs continue to gain traction, it is currently a duopoly market. As analysts expect demand to grow at an encouraging pace, several biotech/pharma companies are rushing to enter this space.
Reddit content is coming to OpenAI’s chatbot, Roche’s weight-loss drug impresses analysts in early-stage trials, and other news to start your day.